Neose Technologies, Inc

About Neose Technologies, Inc

Neose Technologies, Inc. operated as a clinical-stage biopharmaceutical company, established in 1996 and based in Horsham, Pennsylvania. The company concentrated on developing next-generation protein therapeutics by utilizing its proprietary GlycoPEGylation and GlycoAdvance technologies. These technologies were designed to improve existing protein drugs by attaching polyethylene glycol (PEG) polymers to carbohydrate structures on the protein, a method intended to extend the drug's half-life and efficacy while preserving its primary function.

The company's business model focused on applying its core technologies to develop its own pipeline of therapeutic candidates and forming strategic partnerships to enhance the products of other pharmaceutical companies. Revenue generation was structured around upfront payments, research funding, milestone payments, and potential royalties from these collaborations. For instance, a collaboration with BioGeneriX AG included potential milestone payments of up to $61.5 million, plus royalties on sales. Neose's client base consisted of major pharmaceutical and biotechnology firms, such as Novo Nordisk and BioGeneriX AG, a subsidiary of the ratiopharm Group.

Key products in Neose's development pipeline included GlycoPEG-GCSF for treating neutropenia and GlycoPEGylated versions of hemostasis compounds like Factor VIIa, Factor VIII, and Factor IX. These candidates targeted markets with aggregate sales of approximately $8 billion in 2007. C. Boyd Clarke served as the company's president, CEO, and chairman, followed by George J. Vergis as president and CEO.

After an extensive review of strategic alternatives, Neose Technologies announced in September 2008 that it would sell substantially all of its assets to its collaborative partners, Novo Nordisk and BioGeneriX AG, for an aggregate of $43 million in cash. The sale was part of a planned complete liquidation and dissolution of the company, which was approved by stockholders in January 2009. The transaction and subsequent liquidation were deemed to provide the greatest value to the company's stockholders.